Introduction
============

Cancer is the second leading cause of mortality in the United States after heart disease.[@b1-cmar-8-077] Over the years, cancer survival has significantly improved due to a better understanding of cancer biology and the availability of various forms of treatment. One of the core modalities in cancer treatment is chemotherapy. A dreaded side effect, however, is chemotherapy-induced nausea and vomiting (CINV). Treatment for CINV has evolved over the past 2 decades and includes supportive and pharmacologic treatment. Controlling CINV improves the patient's functional status, quality of life, and capacity to perform activities of daily living.[@b2-cmar-8-077],[@b3-cmar-8-077] Nonpharmacologic management of CINV that has been described includes yoga, music therapy, acupressure, Concord grape, and ginger. A systematic review of these interventions has been done and showed insufficient evidence that the said interventions benefit patients with CINV. Non-pharmacologic interventions could be an adjunct given the low risk for toxicities.[@b4-cmar-8-077] An important aspect in the management of CINV is patient education regarding the timing, prevention, and treatment of CINV.[@b5-cmar-8-077] Several medications address the problem of acute and delayed CINV. The medications that are recommended vary with the emetogenic risk of a chemotherapeutic regimen. For highly emetogenic chemotherapy, a combination of a serotonin antagonist 5-hydroxytriptamine 3 (5-HT3), dexamethasone, and neurokinin inhibitor has been recommended. Palonosetron combined with dexamethasone is preferentially used for moderately emetogenic regimens. For low-risk patients, prechemotherapy dexamethasone is offered.[@b3-cmar-8-077],[@b6-cmar-8-077] The introduction of neurokinin inhibitors has greatly improved the ability to prevent and treat persistent CINV in patients receiving moderate to highly emetogenic chemotherapy. This review will focus on the use of the neurokinin inhibitor, fosaprepitant, in the management of CINV.

Pathophysiology of CINV
=======================

CINV is brought about by a complex process involving interconnected neurological pathways, neurotransmitters, and receptors.[@b7-cmar-8-077] Emetogenic receptors are concentrated in three locations in the brainstem: the vomiting center in the medulla oblongata, the chemoreceptor trigger zone in the area postrema in the floor of the fourth ventricle, and the nucleus of the solitary tract. These areas are rich in 5-HT3, neurokinin-1 (NK-1), and dopamine (D) receptors. Serotonin, substance P, and dopamine bind to these receptors, respectively, to initiate the sensation of nausea and the vomiting reflex.[@b8-cmar-8-077]

The gastrointestinal tract is composed of mechanical and chemical receptors. Alterations in the chemical balance of different substances detected by chemoreceptors lead to the activation of vagal afferents, which leads to a cascade of events that then lead to nausea and vomiting.[@b9-cmar-8-077],[@b10-cmar-8-077] Most emetogenic antineoplastic drugs are toxic to the enterochromaffin cells lining the gastrointestinal tract that store and release serotonin. Exposure to these agents leads to the release of serotonin that binds to 5-HT3 receptors in the gut, thereby activating the vagal afferents in the gut and brainstem.[@b11-cmar-8-077],[@b12-cmar-8-077]

The NK-1 receptor is the main receptor for the tachykinin family of peptides that includes substance P. Substance P has also been implicated in the pathogenesis of CINV.[@b13-cmar-8-077] Substance P and NK-1 receptor are found in relevant sites (vagal afferent, nucleus tractus solitarius, and gastrointestinal mucosa) that are essential in the process of emesis. Binding of substance P to NK-1 receptors initiates a cascade of events causing nausea and vomiting. Various stimuli that activate this pathway include chemotherapeutic agents such as cisplatin, radiation, opioids, apomorphine, and electrical stimulation of abdominal vagal afferents. The anatomical localization of these sites has led to the development of antagonists against NK-1 receptor in the treatment of CINV.[@b14-cmar-8-077],[@b9-cmar-8-077]

CINV
====

CINV is a very common side effect of various antineoplastic agents. This greatly affects the quality of life of cancer patients.[@b15-cmar-8-077] Risk factors identified for the development of CINV include female sex, alcohol use, and younger age.[@b16-cmar-8-077]--[@b18-cmar-8-077] These risk factors also predict the failure of antiemetics for both prophylaxis and treatment of CINV ([Table 1](#t1-cmar-8-077){ref-type="table"}).

The risk of CINV also depends on the type of chemotherapy. The emetogenic potential is defined depending on the level of risk: minimal risk (\<10%), low risk (10%--30%), moderate risk (30%--90%), and high risk (\>90%) ([Table 2](#t2-cmar-8-077){ref-type="table"}). CINV is classified based on the timing of occurrence: it may be acute if it occurs within initiation of chemotherapy (lasts \<24 hours), delayed if it occurs after 24 hours (persisting for 6--7 days), or anticipatory (prior to chemotherapy administration).[@b19-cmar-8-077]

Fosaprepitant
=============

Fosaprepitant (Emend for injection -- Merck & Co., Inc., Kenilworth, NJ, USA; Ivemend -- Merck Sharp & Dohme Ltd, Hertfordshire, Europe) is an NK-1 receptor antagonist that is approved for the treatment of CINV. It is an *N*-phosphoryl derivative of aprepitant. The prodrug, fosaprepitant, is converted into the active aprepitant to exert its antiemetic properties.[@b20-cmar-8-077]

It is converted into the active drug, aprepitant, in hepatic and extrahepatic tissues (kidney, lungs, and ileum). Aprepitant is able to cross the blood--brain barrier and block the NK-1 receptor that is widely distributed in the central nervous system. Fosaprepitant has a half-life of approximately 2.3 minutes, with plasma levels below the level of detection in 30 minutes. In the plasma, more than 95% of the drug is protein bound. The volume of distribution of both aprepitant and fosaprepitant is 70 L. Given the high volume of distribution, the drug stays in the body for a longer period of time, hence its efficacy for delayed CINV.[@b21-cmar-8-077]

Aprepitant is metabolized mainly by the CYP3A4, with minor metabolism via the CYP1A2 and CYP2C19. It is a moderate inhibitor of CYP3A4 and inducer of CYP2C9. In contrast, fosaprepitant is a weak inhibitor when administered as a single 150 mg intravenous infusion. This becomes important for patients who take drugs that are likewise metabolized through this process because coadministration will need dose adjustments ([Table 3](#t3-cmar-8-077){ref-type="table"}).[@b21-cmar-8-077],[@b22-cmar-8-077]

Fosaprepitant -- the missing link in antiemesis for cancer patients
===================================================================

Aprepitant is one of the first NK-1 receptor antagonists approved for the prevention and management of nausea and vomiting brought about by moderately and highly emetogenic chemotherapy. It is conventionally administered orally for 3 days (125 mg on Day 1 and 80 mg for Days 2 and 3). It is generally combined with a serotonin antagonist (5-HT3) and dexamethasone. To improve compliance, the prodrug, fosaprepitant, was formulated. This is given as a single dose on Day 1 of chemotherapy as a 150 mg intravenous infusion. That single dose is able to block 90% of NK-1 receptors.[@b21-cmar-8-077],[@b23-cmar-8-077]

A study by Celio et al[@b21-cmar-8-077] compared fosaprepitant and aprepitant in the management of acute and delayed CINV among patients treated with high-dose cisplatin. The results showed that fosaprepitant was noninferior to aprepitant. Both agents are highly efficacious for delayed CINV (nausea and vomiting after 24 hours of chemotherapy).[@b21-cmar-8-077] A randomized, double-blind trial involving 2,322 patients receiving a cisplatin dose of \>70 mg/m^2^ compared aprepitant (with ondansetron and dexamethasone) and fosaprepitant (with ondansetron and dexamethasone). The majority of these patients had lung and gastrointestinal malignancy. The results showed that a single dose of fosaprepitant was noninferior to a 3-day course of aprepitant.[@b23-cmar-8-077]

A 5-day course of aprepitant was compared with a single dose of fosaprepitant in patients receiving highly emetogenic chemotherapy (cisplatin dose \>60 mg/m^2^). There was no significant difference in the efficacy of the incidence of nausea and vomiting 7 days after chemotherapy between the two groups.[@b24-cmar-8-077]

Fosaprepitant has been compared to serotonin antagonist (5-HT3) -- dexamethasone combination, the most common regimen used to treat CINV. A Phase III randomized double-blind study compared a fosaprepitant regimen in combination with granisetron and dexamethasone vs granisetron and dexamethasone only. The end point of the study was a complete response defined as total absence of nausea and vomiting after a high dose of cisplatin. Overall, the fosaprepitant group had better complete response results (64% vs 47%). Fosaprepitant is effective in preventing both acute and delayed CINV, with a complete response of 94% and 65%, respectively.[@b25-cmar-8-077]

Weinstein et al[@b26-cmar-8-077] studied the use of a single-dose fosaprepitant vs ondansetron with dexamethasone for the prevention of CINV. There was no significant difference in the complete response in the acute phase (93.2% vs 91%). However, in the delayed phase, fosaprepitant achieved higher complete response rates (78.9% vs 68.5%; *P*\<0.001).[@b26-cmar-8-077]

A study involving the use of aprepitant or fosaprepitant combined with a 5-HT3 antagonist and dexamethasone in colorectal cancer patients receiving oxaliplatin-based chemotherapy showed that the aprepitant/fosaprepitant group achieved better antiemetic outcomes in the overall response rate and prevention of delayed CINV.[@b27-cmar-8-077]

Kitayama et al[@b28-cmar-8-077] did a prospective randomized crossover study to evaluate the efficacy of palonosetron with dexamethasone vs fosaprepitant with granisetron and dexamethasone in the prevention of CINV among patients receiving moderately emetogenic chemotherapy and found no significant difference between the two groups.

Taking into account all these data, fosaprepitant is effective in the management of CINV, particularly for patients receiving moderately and highly emetogenic chemotherapy. An important benefit is the ability of this medication to control delayed CINV that can develop in the days after chemotherapy administration ([Table 4](#t4-cmar-8-077){ref-type="table"}).[@b5-cmar-8-077]

Venous toxicity
===============

Fosaprepitant, like its oral counterpart aprepitant, is associated with side effects. These usually include anorexia, constipation, nausea, vomiting, diarrhea, hiccups, and asthenia. [@b23-cmar-8-077],[@b25-cmar-8-077] In a study evaluating a single dose of fosaprepitant for the prevention of CINV that included 1,143 patients receiving the drug, the most commonly noted side effects included constipation (10.6%), asthenia (8.6%), diarrhea (7.8%), and vomiting (6.6%).[@b23-cmar-8-077] These adverse events were not significantly different from that of aprepitant. The study of Saito et al[@b25-cmar-8-077] that compared a fosaprepitant regimen to that of granisetron revealed that the most common adverse event of fosaprepitant was leukopenia, which accounted for 59.2% (103 out of 174) followed by anorexia (51.7%) and nausea (43.7%). Infusion site reaction is the major limiting adverse reaction during fosaprepitant administration. One study showed that 23.6% of patients receiving fosaprepitant developed an infusion site reaction.[@b25-cmar-8-077] These reactions include pain, erythema, swelling, extravasation, and phlebitis.[@b29-cmar-8-077]

In several studies, infusion site reactions have been associated with infusion of anthracycline-based chemotherapy. In a study by Sato et al,[@b30-cmar-8-077] fosaprepitant coadministered with an anthracycline-based regimen was associated with a higher incidence (67%) of infusion site reaction compared to regimens without anthracycline (16%). A comparison of fosaprepitant infusion with anthracycline vs a cisplatin-based regimen showed that the former resulted in significantly higher infusion site reaction with an odds ratio of 12.95.[@b31-cmar-8-077] In a study comparing fosaprepitant versus aprepitant when administered with the combined doxorubicin and cyclophosphamide, fosaprepitant resulted in higher infusion site reaction, 34.7% vs 2.3%.[@b32-cmar-8-077] The mechanism of fosaprepitant-induced venous toxicity with an anthracycline-based regimen is poorly understood. A possible hypothesis is that both anthracycline chemotherapy and fosaprepitant cause impaired endothelial function, thus leading to venous toxicity.[@b33-cmar-8-077] Thus, fosaprepitant should be avoided in patients receiving anthracycline, if possible. Otherwise, it should be administered with intravenous fluids in a proximal peripheral venous site as it has been associated with decreased chances of infusion site reaction.[@b34-cmar-8-077] There have been no studies looking into fosaprepitant administration through a central venous access.

Management of CINV
==================

There is variation among the different clinical practice guidelines in the management of CINV. Different medical oncology societies have published their own approach in treating CINV. These guidelines are summarized in [Table 5](#t5-cmar-8-077){ref-type="table"}.

Conclusion
==========

CINV is a major dose-limiting side effect of cancer treatment. Fosaprepitant has been approved for the prevention and treatment of CINV caused by moderately and highly emetogenic chemotherapy. It was found to be more efficacious compared to serotonin antagonist -- dexamethasone drug combination and is noninferior to aprepitant in the management of CINV. With single dosing, it offers better compliance. Infusion site reaction is a major side effect, especially when administered with an anthracycline-based regimen. Infusing in a more proximal peripheral site and with intravenous fluids appears to decrease the chances of venous toxicity.
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###### 

Risk factors for CINV

  Risk factors                      Change in risk
  --------------------------------- --------------------------------------------------------------------------------------------------------------------------------
  Sex                               Greater risk in females
  Age                               Lower incidence at \<6 or \>50 years
  Alcohol consumption               Lower incidence in individuals consuming \>10 alcohol units/week
  Motion sickness                   Prior history leads to greater risk
  Pregnancy-induced emesis          Prior history leads to greater risk
  Anxiety                           High anxiety levels correlated with greater risk
  Previous cycles of chemotherapy   Poorly controlled nausea and vomiting in previous cycles increases the likelihood of CINV and anticipatory nausea and vomiting

**Notes:** Republished with permission of AlphaMed Press, from Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. *Oncologist*. 2003;8(2):187--198; Copyright © 2003 AlphaMed Press; permission conveyed through Copyright Clearance Center, Inc.[@b15-cmar-8-077]

**Abbreviations:** CINV, chemotherapy-induced nausea and vomiting.

###### 

Emetogenic levels of antineoplastic drugs

  Minimal risk   Low risk                    Moderate risk                    High risk
  -------------- --------------------------- -------------------------------- ---------------------------------
  Bevacizumab    Bortezomib                  Carboplatin                      Carmustine
  Bleomycin      Cetuximab                   Cyclophosphamide (≤1.5 g/m^2^)   Cisplatin
  Busulfan       Cytarabine (≤100 mg/m^2^)   Cytarabine (\>1 g/m^2^)          Cyclophosphamide (\>1.5 g/m^2^)
  Cladribine     Docetaxel                   Daunorubicin                     Dacarbazine
  Fludarabine    Etoposide                   Epirubicin                       Mechlorethamine
  Vinblastine    Fluorouracil                Idarubicin                       Streptozocin
  Vincristine    Gemcitabine                 Ifosfamide                       
  Vinorelbine    Ixabepilone                 Irinotecan                       
                 Lapatinib                   Oxaliplatin                      
                 Methotrexate                                                 
                 Mitomycin                                                    
                 Mitoxantrone                                                 
                 Paclitaxel                                                   
                 Pemetrexed                                                   
                 Temsirolimus                                                 
                 Topotecan                                                    
                 Trastuzumab                                                  

**Notes:** From N Engl J Med; Hesketh PJ; Chemotherapy-induced nausea and vomiting; 358(23);2482--2494; Copyright © 2008 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.[@b18-cmar-8-077]

###### 

Drug interactions of (Fos)aprepitant: review of literature and implications for clinical practice

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug class        Major CYP450 pathway                             Comments
  ----------------- ------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------
  Antineoplastics   Alkylating agents (CYP3A4 inhibition)\           Slight increase in blood levels but no clinically significant impact (cyclophosphamide); increases neurotoxicity with ifosphamide
                     Cyclophosphamide\                               
                     Ifosphamide                                     

                    Topoisomerase inhibitor (CYP3A4 inhibition)\     Theoretical increase in blood levels that requires close clinical monitoring
                     Etoposide                                       

                    Microtubule inhibitor (CYP3A4 inhibition)\       Theoretical increase in blood levels that requires close clinical monitoring
                     Docetaxel/paclitaxel                            

                    Tyrosine kinase inhibitor (CYP3A4 inhibition)\   Theoretical increase in blood levels; increased levels noted with Erlotinib that can potentiate antitumor response
                    Crizotinib\                                      
                    Erlotinib                                        

  Opioids           Opioids (CYP3A4 inhibition)\                     Monitor for respiratory depression and sedation
                     Oxycodone\                                      
                     Fentanyl\                                       
                     Hydrocodone\                                    
                    Methadone                                        

  Anticoagulants    Warfarin (CYP2C9 induction)                      Decreases INR that requires close monitoring and increased dosing

                    Apixiban/rivaroxaban (CYP3A4 inhibition)         Potential to increase bleeding that requires close monitoring
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Adapted from Dushenkoy A, Kalabalik J, Carbone A, Jungsuwadee P. *J Oncol Pharm Pract*. Drug interactions with aprepitant or fosaprepitant: review of literature and implications for clinical practice. Epub February 25, 2016. Copyright © 2016 by SAGE Publications. Reprinted by permission of SAGE Publications, Ltd.[@b22-cmar-8-077]

**Abbreviation:** INR, international normalized ratio.

###### 

Summary of clinical trials on fosaprepitant

  Study, location                                   Design                                                   Study patients                                          Type of malignancy                             Sample size   Intervention     Study period     Outcome                   Fosaprepitant regimen                                                                  
  ------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------- ---------------------------------------------- ------------- ---------------- ---------------- ------------------------- ----------------------------------------------- -------------------------------------- -------------
  Grunberg et al,[@b23-cmar-8-077] Canada           Randomized double-blind noninferiority                   Cisplatin based (≥70 mg/m^2^) -- HEC                    Lung, GI, GU, breast                           2,322         F + O + D        A + O + D        1--5 days post-chemo      CR[\*](#tfn6-cmar-8-077){ref-type="table-fn"}   71.9% vs 72.3%; (95% CI −4.1 to 3.3)   Noninferior
  Saito et al,[@b25-cmar-8-077] Japan               Randomized double-blind placebo-controlled superiority   Cisplatin based (≥70 mg/m^2^) -- HEC                    Lung, GI, GU, head and neck                    347           F + G + D        Pl + G + D       1--5 days post-chemo      CR[\*](#tfn6-cmar-8-077){ref-type="table-fn"}   64% vs 47%; *P*=0.001                  Superior
  Ando et al,[@b24-cmar-8-077] Japan                Randomized open-label controlled noninferiority          Patients on cisplatin containing (≥60 mg/m^2^) -- HEC   Lung, GI, head and neck                        93            F + P/G/Az + D   A + P/G/Az + D   1--7 days post-chemo      CR[\*](#tfn6-cmar-8-077){ref-type="table-fn"}   82.2% vs 85.4%; *P*=0.90               Noninferior
  Weinstein et al,[@b26-cmar-8-077] International   Randomized double-blind Phase III superiority            Non-AC chemotherapy regimen -- MEC                      Lung, GI, gynecologic, breast, head and neck   1,015         F + O + D        Pl + O + D       0--120 hours post-chemo   CR[\*](#tfn6-cmar-8-077){ref-type="table-fn"}   77.1% vs 66.9%; *P*\<0.001             Superior
  Nishimura et al,[@b27-cmar-8-077] Japan           Randomized open-label controlled Phase III               Patients on oxaliplatin based -- MEC                    Colorectal                                     413           F/A + O + D      O + D            1--7 days post-chemo      No emesis                                       95.7% vs 83.6%; *P*\<0.0001            Superior
  Kitayama et al,[@b28-cmar-8-077] Japan            crossover                                                Patients on (oxaliplatin/irinotecan based) -- MEC       Colorectal, breast                             35            F + G + D        P + D            1--5 days post-chemo      CR[\*](#tfn6-cmar-8-077){ref-type="table-fn"}   69% vs 74%; *P*=0.56                   Noninferior

**Note:**

No vomiting or use of rescue anti-emetics.

**Abbreviations:** A, aprepitant; AC, adriamycin + cyclophosphamide; Az, azasetron; CI, confidence interval; CR, complete response; D, dexamethasone; F, fosaprepitant; G, granisetron; GI, gastrointestinal; GU, genitourinary; HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; O, ondansetron; P, palonosetron; Pl, placebo; chemo, chemotherapy.

###### 

Clinical practice guidelines in the management of chemotherapy-induced nausea and vomiting

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                          High emetic risk                                                                                                                                         Moderate emetic risk                                                                                  Low emetic risk
  ------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ------------------------------------------------------
  ASCO[a](#tfn8-cmar-8-077){ref-type="table-fn"}          NK-1 antagonist (aprepitant/fosaprepitant) + 5-HT3 antagonist (granisetron/ondansetron/palonosetron/dolasetron/tropisetron/ramosetron) + dexamethasone   Palonosetron + dexamethasone                                                                          Dexamethasone

  NCCN^®,b^                                               NK-1 antagonist (aprepitant/fosaprepitant/rolapitant) + 5-HT3 antagonist (dolasetron/ondansetron/granisetron/palonosetron) + dexamethasone\              5-HT3 antagonist (dolasetron/ondansetron/granisetron/palonosetron) + dexamethasone with or without\   Dexamethasone\
                                                          or\                                                                                                                                                      NK-1 antagonist (aprepitant/fosaprepitant/rolapitant)\                                                or\
                                                          Netupitant + palonosetron + dexamethasone\                                                                                                               or\                                                                                                   prochlorperazine\
                                                          or\                                                                                                                                                      netupitant + palonosetron + dexamethasone\                                                            or\
                                                          Olanzapine + palonosetron + dexamethasone                                                                                                                or\                                                                                                   5-HT3 antagonist(dolasetron/granisetron/ondansetron)
                                                                                                                                                                                                                   olanzapine + palonosetron + dexamethasone                                                             

  ESMO/MASCC[c](#tfn10-cmar-8-077){ref-type="table-fn"}   NK-1 antagonist (aprepitant/fosaprepitant) + 5-HT3 antagonist + dexamethasone                                                                            AC regimen\                                                                                           Dexamethasone\
                                                                                                                                                                                                                   NK-1 antagonist (aprepitant/fosaprepitant) + 5-HT3 antagonist + dexamethasone\                        or\
                                                                                                                                                                                                                   Non-AC regimen palonosetron + dexamethasone                                                           5-HT3 antagonist\
                                                                                                                                                                                                                                                                                                                         or\
                                                                                                                                                                                                                                                                                                                         Dopamine antagonist
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Data from Basch et al.[@b6-cmar-8-077]

Referenced from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®^) for *NCCN Guidelines for Antiemesis V.2.2016*. © National Comprehensive Cancer Network, Inc 2016. All rights reserved. Accessed March 31, 2016. To view the most recent and complete version of the guideline, go online to [www.nccn.org](http://www.nccn.org). NATIONAL COMPREHENSIVE CANCER NETWORK^®^, NCCN^®^, NCCN GUIDELINES^®^, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.[@b35-cmar-8-077]

Adapted from Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. *Annals of Oncology*. 2010;21(Suppl 5):v232--v243. By permission of Oxford University Press on behalf of the European Society for Medical Oncology. This image/content is not covered by the terms of the Creative Commons license of this publication. For permission to reuse, please contact the rights holder. Copyright © 2010, Oxford University Press.[@b36-cmar-8-077]

**Abbreviations:** ASCO, American Society of Clinical Oncology; NCCN, National Comprehensive Cancer Network^®^; ESMO, European Society of Medical Oncology; MASCC, Multinational Association of Supportive Care in Cancer; NK-1, neurokinin-1; 5-HT3, 5-hydroxytriptamine/serotonin; AC, anthracycline/cyclophosphamide.
